Previous close | 31.47 |
Open | 31.60 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 31.38 - 31.60 |
52-week range | 18.68 - 32.36 |
Volume | |
Avg. volume | 1,369 |
Market cap | N/A |
Beta (5Y monthly) | 0.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
JERSEY CITY, N.J., May 07, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the "secured notes") and $500 million of senior unsecured notes due 2034 (the "unsecu
JERSEY CITY, N.J., May 02, 2024--Organon Reports Results for the First Quarter Ended March 31, 2024
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024